Quantcast

Ocular Hypertension Pipeline Review, H1 2020 – Therapeutics Development & Assessment, Companies Involved, Drug Profiles, Dormant Projects, Discontinued Products – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Ocular Hypertension Pipeline Review, H1 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This pipeline guide Ocular Hypertension Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Ocular Hypertension (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ocular Hypertension (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Ocular Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 4, 10, 14, 5 and 7 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Ocular Hypertension (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ocular Hypertension (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Ocular Hypertension (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ocular Hypertension (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ocular Hypertension (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ocular Hypertension (Ophthalmology)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ocular Hypertension (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ocular Hypertension (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered

  1. Introduction
  2. Ocular Hypertension – Overview
  3. Ocular Hypertension – Therapeutics Development
  4. Ocular Hypertension – Therapeutics Assessment
  5. Ocular Hypertension – Companies Involved in Therapeutics Development
  6. Ocular Hypertension – Drug Profiles
  7. Ocular Hypertension – Dormant Projects
  8. Ocular Hypertension – Discontinued Products
  9. Ocular Hypertension – Product Development Milestones

Companies Mentioned

  • Aerie Pharmaceuticals Inc
  • Aerpio Pharmaceuticals Inc
  • Allergan PLC
  • Angelini Group
  • BioIVT
  • Chong Kun Dang Pharmaceutical Corp
  • D. Western Therapeutics Institute Inc
  • Envisia Therapeutics Inc
  • Kedalion Therapeutics Inc
  • Kowa Company Ltd
  • Laboratoires Thea SA
  • Laboratorios Sophia SA de CV
  • Lee’s Pharmaceutical Holdings Ltd
  • Neurim Pharmaceuticals Ltd
  • NicOx SA
  • Novartis AG
  • Noveome Biotherapeutics Inc
  • Ocular Therapeutix Inc
  • Ocuphire Pharma Inc
  • Santen Pharmaceutical Co Ltd
  • Senju Pharmaceutical Co Ltd
  • Shenzhen Hornetcorn Bio-technology Company Ltd
  • Sun Pharma Advanced Research Company Ltd
  • Sustained Nano Systems LLC
  • Sylentis SAU
  • Taejoon Pharm Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • ViSci Ltd
  • Whitecap Biosciences LLC

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/m9b99y

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Read the full article

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.